Trial
NCT05038020
A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Alkahest, Inc.
Collaborators
—
Condition
Diabetic Retinopathy
Intervention
AKST4290
Why stopped
Study terminated due to safety findings in other AKST4290 studies
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-01